Citation, DOI, disclosures and article data
At the time the article was created Frank Gaillard had no recorded disclosures.View Frank Gaillard's current disclosures
Peritoneal metastases are a relatively common location for metastases, particularly from tumors of the abdomen and pelvis, that generally imply a poor prognosis, often with a significant impact on palliation 1.
If peritoneal metastases are of an epithelial origin (as most are) and extensive, the term peritoneal carcinomatosis may also be used. Less commonly, peritoneal metastases arise from mesodermal or lymphoid cell lines, with peritoneal sarcomatosis or peritoneal lymphomatosis respectively as the preferred terms 1.
The epidemiology of patients with peritoneal metastases mirrors that of affected patients. Common primaries include 1,2:
extra-adrenal, intra-abdominal paraganglioma 5
Isolated peritoneal metastases are usually asymptomatic. Peritoneal carcinomatosis may also be asymptomatic, but eventually, most patients begin to report symptoms which can vary from uncomfortable to debilitating. Symptoms include 1:
abdominal distention due to malignant ascites
abnormal bowel motility, resulting
bowel obstruction (most common from colorectal cancer metastases)
Malignant involvement of the peritoneal lining occurs via a number of routes, including 1:
intraperitoneal seeding and direct invasion: most common
lymphatic dissemination: rare
Although peritoneal metastases are visible on ultrasound, MRI and sometimes are implied on barium studies, CT is the most frequently used modality to investigate patients with suspected peritoneal metastases, or assess the resultant complications.
Malignant ascites may be anechoic or have low-level echoes, and aids in the identification of deposits 1. Nodules are of intermediate echogenicity, hypoechoic compared to the peritoneum, whereas infiltration of the omentum results in hyperechogenicity 1.
Peritoneal metastases can range in appearance from invisible to multiple large masses, and historically CT can only detect 60-80% of peritoneal metastases later shown to be present at surgery, although more recent studies reported detection rates of 85-93% 1,3. Appearances include 1:
thickening and enhancement of peritoneal reflections (especially if nodular)
soft tissue nodules
stranding and thickening of the omentum (omental cake)
stranding and distortion of the small bowel mesentery
ascites, especially if loculated
calcifications 2 (particularly in cystadenocarcinoma of the ovary)
nodular with the non-calcified component are typical
Intraperitoneal contrast has been investigated as a way of improving sensitivity to the presence of small deposits, and may improve detection but has not been widely adopted 3.
MRI can be very sensitive, probably more so than CT (85-90%) 1. Peritoneal metastases show up as increased enhancement (greater than liver), best seen after 5-10 minutes 1.
Treatment and prognosis
Peritoneal metastases per se are not locally treated, although systemic treatment may have some effect. Complications do however frequently require treatment for palliation:
bowel obstruction: bypass enterostomies may be required
malignant ascites: repeated ascitic drainage
Differential diagnosis depends on the dominant pattern.
peritoneal mesothelioma is very similar to peritoneal carcinomatosis, but usually no primary neoplasm is known
peritoneal sarcomatosis: if the primary tumor is of mesenchymal origin (i.e. sarcoma)
most commonly metastases from a gastrointestinal sarcoma 1
most commonly metastases from a primary (e.g. non-Hodgkin lymphoma) elsewhere 1
smooth thickening and enhancement of the peritoneum, with stranding of the omentum and mesentery may be seen in intra-abdominal sepsis
benign calcifications tend to be sheetlike, and nodal calcifications in these patients less common 2
a history of peritoneal dialysis or recent abdominal sepsis is usually easily obtained
- 1. Levy AD, Shaw JC, Sobin LH. Secondary tumors and tumorlike lesions of the peritoneal cavity: imaging features with pathologic correlation. Radiographics. 29 (2): 347-73. doi:10.1148/rg.292085189 - Pubmed citation5. Cabral, F., Krajewski, K., Kim, K., Ramaiya, N. and Jagannathan, J. (2013). Peritoneal lymphomatosis: CT and PET/CT findings and how to differentiate between carcinomatosis and sarcomatosis. Cancer Imaging, 13(2), pp.162-170.
- 2. Agarwal A, Yeh BM, Breiman RS et-al. Peritoneal calcification: causes and distinguishing features on CT. AJR Am J Roentgenol. 2004;182 (2): 441-5. AJR Am J Roentgenol (citation) - Pubmed 1. citation
- 3. Halvorsen RA, Panushka C, Oakley GJ et-al. Intraperitoneal contrast material improves the CT detection of peritoneal metastases. AJR Am J Roentgenol. 1991;157 (1): 37-40. AJR Am J Roentgenol (citation) - Pubmed 2. citation
- 4. Kurra V, Katherine M, Krajewski, J Jagannathan,et al. Typical and atypical metastatic sites of recurrent endometrial carcinoma. (2018) Cancer Imaging. 13 (1): 113. doi:10.1102/1470-7330.2013.0011 - Pubmed
- 5. S Hillewaere, L Stessens, K Van der Speeten. An Unusual Case of Peritoneal Carcinomatosis. (2018) Case Reports in Oncology. 3 (3): 315. doi:10.1159/000320623 - Pubmed
- 6. Chrysikopoulos H, Maniatis V, Roussakis A, et al. Peritoneal metastases from transitional cell carcinoma of the urinary tract: CT and MR imaging. (1998) Abdominal imaging. 23 (1): 91-5. Pubmed
- 7. Pasqual E, Bertozzi S, Londero A et al. Microscopic Peritoneal Carcinomatosis in Gastric Cancer: Prevalence, Prognosis and Predictive Factors. Oncol Lett. 2018;15(1):710-6. doi:10.3892/ol.2017.7442 - Pubmed
- 8. Yarema R, Оhorchak М, Hyrya P et al. Gastric Cancer with Peritoneal Metastases: Efficiency of Standard Treatment Methods. World J Gastrointest Oncol. 2020;12(5):569-81. doi:10.4251/wjgo.v12.i5.569 - Pubmed